In a powerful move to put American patients first, President Donald J. Trump has signed a groundbreaking Executive Order implementing a Most Favored Nation pricing model for prescription drugs. This transformative action is set to deliver significantly lower drug prices for American families and taxpayers—ensuring that we no longer pay more than other wealthy nations for the same medications.
Lowering Drug Costs for Americans and Taxpayers
With this new Executive Order, President Trump is once again fighting for fairness and affordability in our healthcare system. The Order ensures that Americans will benefit from the same discounted drug prices that other developed countries enjoy. Here’s how it works:
The U.S. Trade Representative and Secretary of Commerce will hold foreign countries accountable if they engage in unfair practices that push up drug prices in the U.S.
Pharmaceutical companies will be required to meet pricing targets that reflect America’s status as the largest purchaser of prescription drugs in the world.
A new system will allow American patients to buy medications directly from manufacturers at “Most-Favored-Nation” prices—cutting out costly middlemen.
If drugmakers refuse to cooperate, the Secretary of Health and Human Services is authorized to implement tough rules and take aggressive steps to drive prices down and break up anticompetitive practices.
A Better Deal for the American People
For too long, Americans have carried an unfair burden—paying over three times more for brand-name drugs than citizens in other developed nations. Despite making up less than five percent of the global population, the U.S. foots the bill for nearly 75% of global pharmaceutical profits. President Trump is putting an end to this imbalance.
Drug manufacturers often slash prices abroad to enter foreign markets, then pass the cost on to American consumers. This Executive Order sends a clear message: the days of Americans subsidizing foreign healthcare systems are over.During his first term, President Trump worked to ensure that Medicare beneficiaries would no longer overpay for drugs compared to patients in similar countries.
Unfortunately, the Biden Administration canceled those reforms—only to replace them with negotiations that left Americans still paying an average of 78% more than people in 11 comparable nations.
Putting American Patients First—Again
This latest Executive Order is part of a broader campaign by President Trump to prioritize American health and economic well-being:
It expands prior reforms to include both Medicare and Medicaid, increasing access to affordable medicines across the board.
It offers significant discounts to low-income patients on lifesaving medications and promotes programs that allow states to import safe, affordable drugs.
It supports the availability of lower-cost generic and biosimilar medicines.
It continues President Trump’s historic push for transparency in drug pricing, so Americans can finally know what they’re paying for—and why.
President Trump’s commitment to healthcare fairness is clear: he’s delivering real results that put patients before profits and America before bureaucracy. This Executive Order marks a major step toward ending price gouging and restoring balance to our healthcare system.
Bottom line: Americans deserve a fair price for prescription drugs—and President Trump is making it happen.
